FMFarid Mallat

Farid Mallat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Farid Mallat has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Twist-Drill Evacuation of Chronic Subdural Hematoma: Clinical Correlation with Postoperative Radiological Findings

    by Elias Al Helou, Farid Mallat, Sandra Kobaiter-Maarrawi, Ghady Zgheib, Ralph Abdallah, Joseph Maarrawi

  • Open Access

    Morpho-clinical insights into moderate-to-severe obstructive sleep apnea

    by Moussa Riachy, Sophie Riachy, Albert Riachy, Farid Mallat, Nicolas Medawar, Thalia Hanna, Kristy Braidy, Dalia Al Halabi, Joe Elio El Chaer, Karl Chammas, et al.

  • Open Access

    Effective Intramuscular Vitamin D2 in Patients with Systemic Sclerosis Non-Responding to Oral Supplementation; A Retrospective Observational Case Series

    by Maroun Aoun, Farid Mallat, Rita Jabbour, Samir Hachem, Boutros Soutou, Josiane Helou

    Objective: To assess the response to intramuscular vitamin D in patients not respond-ing to oral supplementation. Methods: A retrospective series included patients, with systemic sclerosis and a history of subclinical poor vitamin D status that was resistant to at least 6 months of oral supplementation, to whom intramuscular vitamin D2 was administered. Results: Twelve patients were identified, with a mean age of 47.8 years. All were women. Five had diffuse systemic sclerosis and seven had localized systemic sclerosis. The mean duration of the disease was 17.9 years, with a mean modified Rod-nan skin score of 14.9. All patients were twice injected, at a 15-day interval, 300,000 IU of ergocalciferol into the anterior gluteus muscle. The mean serum level of 25(OH)D increased from 12.9 ng/mL before the first injection, to 23 ng/mL two weeks after the first injection, and 37.1 ng/mL four weeks after the second injection (p<0.001). No side effects were observed. Conclusion: It is the first report of safely normalizing vitamin D levels with intramuscular ergocalciferol in patients with systemic sclerosis.

  • Open Access

    Insights Into the Emerging Entity of HER2‐Low Breast Cancer

    by Georges El Haddad, Ernest Diab, Michel Hajjar, Maroun Aoun, Farid Mallat, Ziad Zalaquett, Hampig-Raphael Kourie

    Human epidermal growth factor receptor 2 (HER2)‐low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other more aggressive BC subtypes. Early studies suggest that it may have a more favorable prognosis than HER2‐positive BC, as it is less likely to spread to other parts of the body and may be more responsive to standard BC treatments such as chemotherapy, radiation therapy, and hormone therapy. Given the relative new emergence of HER2‐low BC, there is still much to be learned about this subtype; ongoing research is focused on identifying the underlying genetic mutations that contribute to HER2‐low BC as well as developing targeted therapies that can improve outcomes for patients with this disease. This review is aimed at summarizing the current clinical knowledge on HER2‐low BC, with the aim of creating a better understanding of this entity and paving the way for potential interventions and a new standard of care.


  • Botulinum Toxins and Zinc: From Theory to Practice—A Systematic Review

    by Farid Bsc Mallat, Jerome Kaikati, Elio Md Kechichian

    Objective: The aims of this study were to determine whether zinc supplementation affects botulinum toxin's effect and longevity and to establish a transition from the molecular to the clinical aspect. Methods: We conducted a systematic review in which we included all published studies on PubMed and Embase using the combination of the following terms: “zinc” AND (botox OR botulinum OR onabotulinumtoxinA OR abobotulinumtoxinA OR incobotulinumtoxinA). Results: From the 260 yielded articles, 3 randomized control trials and 1 case report were retained. Three of them found a significant improvement with zinc supplementation in the toxin's effect and longevity. This was observed in neurological conditions and cosmetic uses. Conclusions: Zinc supplementation could be an interesting asset in the potentialization of botulinum neurotoxin effect and longevity. Larger clinical trials and objective measurement tools should be used to further defining the role of zinc in maximizing botulinum neurotoxin effect.